Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 10, 2008, Pages 1391-1397

  Hušek, Petr ^a,b,c   Švagera, Zdeněk ^a   Všianský, František ^a   Franeková, Janka ^a   Šimek, Petr ^b  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c Faculty Hospital Ostrava   (Czech Republic)

Author keywords

Alendronate therapy; Diet related effects; Osteopathies and osteomarkers; Postmenopausal osteoporosis; Prolyl hydroxyproline dipeptide

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; COLLAGEN TYPE 1; CREATININE; DEOXYPYRIDINOLINE; DIPEPTIDE; OSTEOCALCIN; PROLYL 4 HYDROXYPROLINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE DENSITOMETRY; BONE TURNOVER; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; DIPEPTIDES; FEMALE; HUMANS; HYDROLYSIS; HYDROXYPROLINE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 53849148238     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.259     Document Type: Article

References (33)

1. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
2. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. J Am Med Assoc 2002;288:1889-97.
3. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11(Suppl 6):S66-76.
4. Garnero P, Delmas PD. [Biochemical markers of bone turnover: clinical usefulness in osteoporosis]. Anal Biol Clin (Paris) 1999;57:137-48. In French.
5. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999;2:323-42.
6. Watts NB. Clinical utility of biochemical markers of bone remodeling. Rev Clin Chem 1999;45:1359-68.
7. Hodgkinson A, Thompson T. Measurement of the fasting urinary hydroxyproline: creatinine ratio in normal adults and its variation with age and sex. J Clin Pathol 1982;35:807-11.
8. Palicka V, Jabor A, Friedecký B, Zivný P. Selected markers of bone biochemistry. Adv Clin Chem 2001;35:255-94.
9. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11(Suppl 6):S2-17.
10. Beck-Jensen JE, Kollerup G, Soerensen HA, Pors Nielsen S, Soerensen OH. A single measurement of biochemical markers of bone turnover has limited utility in the individual persons. Scand J Clin Lab Invest 1997;57:351-60.
11. Blumsohn A, Eastell R. The performance and utility of biochemical markers of bone turnover: do we know enough to use them in clinical practice? Ann Clin Biochem 1997;34:449-59.
12. Mazzi G, Fioravanzo F, Burti E. New marker of bone resorption: hydroxyproline-containing peptide. HPLC assay without hydrolysis as an alternative to hydroxyproline determination: a preliminary report. J Chromatogr B 1996;678:165-72.
13. Faull KF, Schier GM, Schlesinger P, Halpern B. The mass spectrometric identification of dipeptides in the urine of a patient suffering from chronic skin ulceration and oedema. Clin Chim Acta 1976;70:313-21.
14. Charpentier C, Johnstone RA, Lemonnier A, Myara I, Rose ME, Tuli D. Analysis of dipeptides in urine by gas chromatography/mass spectrometry: implications for collagen breakdown in iminodipeptiduria following a study of the dipeptides by electron impact and chemical ionization Clin Chim Acta 1984;138:299-308.
15. Bienenstock H, Kibrick AC. Urinary excretion of prolylhydroxyproline in rheumatic diseases. Ann Rheum Dis 1969;28:28-30.
16. Weiss PH, Klein LR. The quantitative relationship of urinary peptide hydroxyproline excretion to collagen degradation. J Clin Invest 1969;48:1-10.
17. Pohlídal A, Hušek P, Palicka V, Slabík D, Hill M, Matucha P. Novel and traditional biomarkers of bone turnover in postmenopausal women. Clin Chem Lab Med 2003;41:74-8.
18. Pohlídal A. Investigation on significance and utility of biomarkers of bone tissue turnover in diagnostics and pharmacotherapy of osteoporosis. Ph.D. dissertation. School of Medicine, Hradec Králové, Czech Republic, 2002:2-161.
19. Hušek P, Pohlídal A, Slabik D. Rapid screening of urinary proline-hydroxyproline dipeptide in bone turnover studies. J Chromatogr B 2002;767:169-74.
20. Stepan JJ, Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta 1999;288:121-35.
21. Prentice A. Diet, nutrition and the prevention of osteoporosis. Publ Health Nutr 2004;7:227-43.
22. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003;78(Suppl 3):593s-609s.
23. Weaver CM, Liebman M. Biomarkers of bone health appropriate for evaluating functional foods designed to reduce risk of osteoporosis. Br J Nutr 2002;88(Suppl 2):225s-32s.
24. Cashman KD. Diet, nutrition, and bone health. J Nutr 2007;137(Suppl 11):2507s-12s.
25. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-40.
26. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008;42:623-30.
27. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005;90:2762-7.
28. Chailurkit L, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R. Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 2001;47:1083-8.
29. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy of free and peptide-bound bone crosslinks excretion. J Bone Miner Res 1995;10:641-9.
30. Apone S, Lee MY, Eyre DR. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997;21:129-36.
31. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
32. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15:594-8.
33. Šimek P, Hušek P, Cimlová J, Texlová M. Immediate in situ derivatization of urinary prolyl-hydroxyproline dipeptide with alkyl chloroformates for LC-MS/MS analysis. J Mass Spectroscopy. In preparation.